|
Shanghai Genechem Ltd
sik2 knockdown lentivirus with green fluorescent protein Sik2 Knockdown Lentivirus With Green Fluorescent Protein, supplied by Shanghai Genechem Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/sik2 knockdown lentivirus with green fluorescent protein/product/Shanghai Genechem Ltd Average 90 stars, based on 1 article reviews
sik2 knockdown lentivirus with green fluorescent protein - by Bioz Stars,
2026-02
90/100 stars
|
Buy from Supplier |
|
CH Instruments
sik2 protein ![]() Sik2 Protein, supplied by CH Instruments, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/sik2 protein/product/CH Instruments Average 90 stars, based on 1 article reviews
sik2 protein - by Bioz Stars,
2026-02
90/100 stars
|
Buy from Supplier |
Image Search Results
Journal: Cancer cell
Article Title: SIK2 is a centrosome kinase required for bipolar mitotic spindle formation that provides a potential target for therapy in ovarian cancer
doi: 10.1016/j.ccr.2010.06.018
Figure Lengend Snippet: A–D) SKOv3 cells were transfected with either non-targeting siRNA (A) or SIK2 siRNA (B) for 48 hr then monitored for 16 hr (one image every 5 minutes) using bright field phase-contrast microscopy. The time interval from nuclear envelope breakdown (0:00 in A and B) to anaphase onset (01:20 in control cells) was estimated. Arrows point to the cell under study. Time is shown as hours:minutes. Scale bar, 10 µm. In C Western blot confirmation of knockdown of SIK2 using 3 independent siRNAs compared to non-targeting siRNA control is shown. r-GST-SIK2; recombinant GST-tagged SIK2 was used on the same Western blot to confirm the antibody specificity. D) The mean ± s.e.m of the mitotic transition time (obtained as in A and B) is presented following control and SIK2 siRNA transfections. In E, SKOv3 cells (5000 cells per well) were reverse transfected in 96 well plates using either non-targeting controls or SIK2 siRNAs A, B and C for 24 hr and cells were then either a) fixed and stained using crystal violet to estimate the number of cells on the day of paclitaxel treatment (Day 0) or b) treated with either diluent or paclitaxel at 9 different concentrations. The latter group of cells was fixed and stained 72 hr following drug treatment. Growth of cells from day 0 to day 3 was estimated and the percentage paclitaxel-induced growth inhibition for each siRNA in relation to diluent treated cells transfected with the same siRNA was calculated and a least-squares fit was obtained to estimate the GI 50 as described in methods (Monks et al., 1991). Shown is the mean ± s.e.m from three replicates per concentration. In F the effect of depletion of SIK2 using siRNA C on paclitaxel response in three cell lines is shown. The experiment was conducted as in E. Shown is the mean ± s.e.m from six replicates per concentration. Also shown is the p value for the comparison between the GI 50 in cells transfected with non-targeting siRNA control v cells transfected with SIK2 siRNA. G) Microarray expression data for two probe sets representing SIK2 were used to generate Kaplan Meier survival curves for high expressing (defined as cancers with values above the median + (0.5 × median absolute deviation [MAD]) or low expressing (below the median − (0.5 × MAD) for 229 high-grade serous (HGS) ovarian cancers. See also Figure S2 and Movies Smov1–3.
Article Snippet: However, in G2,
Techniques: Transfection, Microscopy, Control, Western Blot, Knockdown, Recombinant, Staining, Inhibition, Concentration Assay, Comparison, Microarray, Expressing
Journal: Cancer cell
Article Title: SIK2 is a centrosome kinase required for bipolar mitotic spindle formation that provides a potential target for therapy in ovarian cancer
doi: 10.1016/j.ccr.2010.06.018
Figure Lengend Snippet: A) SKOv3 cells were fixed and stained for immunofluorescence (IF) using the indicated antibodies to show the co-localization between SIK2 and γ-tubulin. B) The co-localization of ectopically expressed myc-tagged SIK2 with γ-tubulin in SKOv3 cells is shown. Also note the peri-centrosomal expression of SIK2. Scale bar, 5 µm. See also Figure S3.
Article Snippet: However, in G2,
Techniques: Staining, Immunofluorescence, Expressing
Journal: Cancer cell
Article Title: SIK2 is a centrosome kinase required for bipolar mitotic spindle formation that provides a potential target for therapy in ovarian cancer
doi: 10.1016/j.ccr.2010.06.018
Figure Lengend Snippet: A) SKOv3 cells were transfected with myc/flag-tagged wild type SIK2 or myc/flag-tagged kinase mutant SIK2 (SIK2_mt) plasmid for 24 hr then cells were fixed and stained using anti-myc antibody (red), and anti-γ-tubulin antibody (green). Arrow heads show an example of CS (inter-centrosome distance > 2µm) following SIK2 transfection. B–C) Mean ± s.e.m of the percentage of cells with CS 24 hr following transfection using the indicated plasmids. Overexpression of NEK2, which is known to induce CS, was used as a positive control in this experiment. Experiments were performed at least in triplicates. Scale bar, 5 µm.
Article Snippet: However, in G2,
Techniques: Transfection, Mutagenesis, Plasmid Preparation, Staining, Over Expression, Positive Control
Journal: Cancer cell
Article Title: SIK2 is a centrosome kinase required for bipolar mitotic spindle formation that provides a potential target for therapy in ovarian cancer
doi: 10.1016/j.ccr.2010.06.018
Figure Lengend Snippet: A–E)Cancer cells were transfected with siRNAs for 48 hr as indicated then fixed and stained. In A and B SKOv3 cells were stained using anti-γ-tubulin (red) and anti-phosphohistone H3 (green) to reveal the centosome position in mitosis in relation to chromosomes. Note the presence of examples from different mitosis phases in control cells (1–4; prophase, prometaphase, metaphase and anaphase, respectively) compared to the predominance of prometaphase cells following SIK2 KD. Also shown are examples of multipolar (I) and monopolar (II) centrosome positioning following SIK2 KD. Bar plots in B and D represent the mean ± s.d. of the percentages of cells at different stages of mitosis. Bar plots in C represent the mean prometaphase/metaphase ratio ± standard deviation. F–G) DMEL Drosophila cells were transfected using non-targeting control double stranded RNA (dsRNA) or dsRNAs targeting the Drosophila orthologue of SIK2. Examples of mitotic cells with failed centrosome separation are presented in F. In G, the mean ± s.d. of mitotic cells with failed centrosome separation from three independent experiments is shown. Scale bars, 10 µm. See also Figure S5.
Article Snippet: However, in G2,
Techniques: Transfection, Staining, Control, Standard Deviation
Journal: Cancer cell
Article Title: SIK2 is a centrosome kinase required for bipolar mitotic spindle formation that provides a potential target for therapy in ovarian cancer
doi: 10.1016/j.ccr.2010.06.018
Figure Lengend Snippet: A-SKOv3 cells were transfected with the indicated siRNAs for 72 hours then fixed and stained. The centrosome expression of PRKAR2A is present in control cells (arrow) but absent following KD of AKAP450 (I and II). B) Bar plots represent the mean ± s.d. of triplicate percentages of cells with CS following transfection with the indicated siRNAs. Depletion of AKAP450 resulted in a significant increase in CS while co-depletion of AKAP450 and SIK2 rescued this phenotype. Scale bar, 5 µm. See also Figure S6.
Article Snippet: However, in G2,
Techniques: Transfection, Staining, Expressing, Control
Journal: Cancer cell
Article Title: SIK2 is a centrosome kinase required for bipolar mitotic spindle formation that provides a potential target for therapy in ovarian cancer
doi: 10.1016/j.ccr.2010.06.018
Figure Lengend Snippet: A) SKOv3, ES2 and Hey cells were either transfected using non-targeting control siRNA or the indicated SIK2 siRNAs for 5 days. Cells were fixed and stained using crystal violet. Shown is the mean ± s.e.m. of 12 replicate values per siRNA transfection type from two independent experiments in SKOv3 cells. ** indicates p<0.001. Error bars for Hey and ES2 cells represent the s.e.m. of 6 replicate values per siRNA transfection type from two independent experiments. B) Typical cell cycle distributions are presented following transfection of SKOv3 cells with the indicated siRNAs. C) Cells were transfected using the indicated siRNA for 48 hr then treated with paclitaxel 100 nM for 24 hr, fixed and stained using anti-phosphohistone H3 antibody to calculate the mitotic index (MI) using flow cytometry. Shown is the mean MI (± s.d.) of two independent experiments. D) Cell lines were transfected with the indicated SIK2 siRNAs and control non-targeting siRNAs for 48 hr then harvested for analysis of protein expression using reverse phase protein arrays. Shown is the fraction of expression of AKT-pS437 and total AKT following SIK2 siRNA transfection relative to protein expression following non-targeting siRNAs. E) The expression of 139 proteins (Supplementary Table S4) was estimated using reverse phase protein arrays as in D following transfection of cancer cells using three SIK2 siRNAs and one non-targeting control in 3 cell lines; SKOv3, Hey and ES2. The expression of each of the 139 proteins was correlated with cancer cell growth that was measured in A. Each bar represents the coefficient of the correlation between the expression of each of the proteins in 9 cell lines (3 SIK2 siRNAs × 3 cell lines) and the growth of the cancer cell line from which the protein was measured. Positive values indicate that higher expression of a protein correlates with more cancer cell growth. Negative values indicate that higher expression correlate with poor growth. F) Shown is the regression lines for the correlation between the fraction of ovarian cancer cell proliferation following SIK2 depletion relative to non-targeting control and the fraction expression of AKT-pS437 or total AKT following SIK2 depletion relative to non-targeting controls. See also Figure S7 and Table S4.
Article Snippet: However, in G2,
Techniques: Transfection, Control, Staining, Flow Cytometry, Expressing
Journal: Cancer cell
Article Title: SIK2 is a centrosome kinase required for bipolar mitotic spindle formation that provides a potential target for therapy in ovarian cancer
doi: 10.1016/j.ccr.2010.06.018
Figure Lengend Snippet: A) A flow diagram showing the design of the in vivo experiment. B) Immunohistochemical confirmation of SIK2 depletion in SKOv3ip1 tissue sections using anti-SIK2 antibody. Scale bar, 50 µm. C–F) 5 µm sections from tumors were stained using the indicated antibodies. C–D) sections were stained using the indicated antibodies to calculate the mitotic index per field by manually counting phospho-Histone H3 positive nuclei and total number of nuclei. Shown in C is the mean ± s.e.m. of the MIs from 7 fields from two mice. In E an example of monopolar centrosome orientation following SIK2 KD in mice is shown. F) Bar plot representation of the mean ± s.e.m. of the percentage of mitotics with monopolar centrosome orientation from two mice (two slides per mouse). G–H) Mean tumor weights (± s.d.) obtained from 10 mice per siRNA type in SKOv3 cells and Hey cells. Scale bar, 10 µm.
Article Snippet: However, in G2,
Techniques: In Vivo, Immunohistochemical staining, Staining